Notice2022-10240
Notice Pursuant to the National Cooperative Research and Production Act of 1993-Subcutaneous Drug Development & Delivery Consortium, Inc.
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
May 13, 2022
Issuing agencies
Justice DepartmentAntitrust Division
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 93 (Friday, May 13, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 93 (Friday, May 13, 2022)]
[Notices]
[Page 29381]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-10240]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Antitrust Division
Notice Pursuant to the National Cooperative Research and
Production Act of 1993--Subcutaneous Drug Development & Delivery
Consortium, Inc.
Notice is hereby given that, on April 25, 2022, pursuant to Section
6(a) of the National Cooperative Research and Production Act of 1993,
15 U.S.C. 4301 et seq. (``the Act''), Subcutaneous Drug Development &
Delivery Consortium, Inc. (``Subcutaneous Drug Development & Delivery
Consortium, Inc.'') has filed written notifications simultaneously with
the Attorney General and the Federal Trade Commission disclosing
changes in its membership. The notifications were filed for the purpose
of extending the Act's provisions limiting the recovery of antitrust
plaintiffs to actual damages under specified circumstances.
Specifically, Roche Holding AG, Basel, SWITZERLAND, has been added as a
party to this venture.
No other changes have been made in either the membership or planned
activity of the group research project. Membership in this group
research project remains open, and Subcutaneous Drug Development &
Delivery Consortium, Inc. intends to file additional written
notifications disclosing all changes in membership.
On October 26, 2020, Subcutaneous Drug Development & Delivery
Consortium, Inc. filed its original notification pursuant to Section
6(a) of the Act. The Department of Justice published a notice in the
Federal Register pursuant to Section 6(b) of the Act on December 3,
2020 (85 FR 78148).
The last notification was filed with the Department on December 8,
2021. A notice was published in the Federal Register pursuant to
Section 6(b) of the Act on January 13, 2022 (87 FR 2182).
Suzanne Morris,
Chief, Premerger and Division Statistics, Antitrust Division.
[FR Doc. 2022-10240 Filed 5-12-22; 8:45 am]
BILLING CODE 4410-11-P
</pre></body>
</html>Indexed from Federal Register on May 13, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.